Strs Ohio Has $977,000 Stock Holdings in Genomic Health, Inc. (NASDAQ:GHDX)

Strs Ohio increased its stake in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 30.2% in the second quarter, Holdings Channel.com reports. The firm owned 16,800 shares of the medical research company’s stock after buying an additional 3,900 shares during the quarter. Strs Ohio’s holdings in Genomic Health were worth $977,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in GHDX. Norges Bank acquired a new position in Genomic Health during the 4th quarter worth approximately $20,975,000. Fiera Capital Corp acquired a new position in Genomic Health during the 1st quarter worth approximately $20,134,000. FMR LLC increased its position in Genomic Health by 83.8% during the 4th quarter. FMR LLC now owns 550,627 shares of the medical research company’s stock worth $35,466,000 after purchasing an additional 251,085 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Genomic Health by 269.2% during the 1st quarter. Assenagon Asset Management S.A. now owns 267,410 shares of the medical research company’s stock worth $18,732,000 after purchasing an additional 194,988 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in Genomic Health by 20.5% during the 1st quarter. Acadian Asset Management LLC now owns 893,114 shares of the medical research company’s stock worth $62,561,000 after purchasing an additional 151,846 shares in the last quarter. Institutional investors and hedge funds own 95.63% of the company’s stock.

GHDX opened at $74.90 on Wednesday. Genomic Health, Inc. has a fifty-two week low of $50.77 and a fifty-two week high of $92.18. The company has a quick ratio of 5.74, a current ratio of 5.74 and a debt-to-equity ratio of 0.17. The company has a market cap of $2.74 billion, a price-to-earnings ratio of 71.33 and a beta of 1.06. The stock’s 50 day simple moving average is $63.20.

Genomic Health (NASDAQ:GHDX) last posted its earnings results on Monday, July 29th. The medical research company reported $0.42 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.07. Genomic Health had a net margin of 11.69% and a return on equity of 19.51%. The firm had revenue of $114.14 million for the quarter, compared to analyst estimates of $110.78 million. During the same period in the previous year, the firm posted $0.23 EPS. The company’s revenue for the quarter was up 19.4% compared to the same quarter last year. As a group, research analysts expect that Genomic Health, Inc. will post 1.5 EPS for the current fiscal year.

In other news, CEO Kimberly J. Popovits sold 25,000 shares of the company’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $73.85, for a total value of $1,846,250.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Steven Shak sold 50,000 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $51.38, for a total transaction of $2,569,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 290,601 shares of company stock worth $18,833,446 over the last three months. Insiders own 31.30% of the company’s stock.

GHDX has been the subject of a number of research analyst reports. Barclays upgraded shares of Genomic Health from an “underweight” rating to an “equal weight” rating and upped their price objective for the stock from $45.00 to $72.00 in a research report on Tuesday, July 30th. Needham & Company LLC cut shares of Genomic Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 30th. Canaccord Genuity cut shares of Genomic Health from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $77.00 to $72.00 in a research report on Tuesday, July 30th. Deutsche Bank lowered their price objective on shares of Genomic Health from $80.00 to $55.00 and set a “hold” rating for the company in a research report on Thursday, May 30th. Finally, BidaskClub upgraded shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 6th. Nine equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $69.86.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Article: Growth Stocks

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.